WealthTrust Axiom LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 20.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,541 shares of the biopharmaceutical company’s stock after buying an additional 3,303 shares during the period. WealthTrust Axiom LLC’s holdings in Gilead Sciences were worth $1,327,000 as of its most recent filing with the SEC.
Several other large investors also recently modified their holdings of GILD. Hall Laurie J Trustee raised its stake in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares during the last quarter. Cable Hill Partners LLC raised its stake in shares of Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares during the last quarter. Dubuque Bank & Trust Co. raised its stake in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares during the last quarter. Thomas J. Herzfeld Advisors Inc. bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $143,000. Finally, Perennial Advisors LLC bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $150,000. Institutional investors own 73.99% of the company’s stock.
Shares of Gilead Sciences, Inc. (GILD) opened at 64.82 on Tuesday. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $88.85. The firm has a market cap of $84.70 billion, a P/E ratio of 6.85 and a beta of 1.20. The company’s 50-day moving average is $65.54 and its 200-day moving average is $69.05. Gilead Sciences also saw unusually large options trading on Monday. Traders acquired 22,560 call options on the company. This is an increase of 103% compared to the typical volume of 11,118 call options.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.18 by $0.02. Gilead Sciences had a return on equity of 76.64% and a net margin of 43.42%. The company had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.66 billion. Equities research analysts forecast that Gilead Sciences, Inc. will post $8.20 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, June 29th. Stockholders of record on Friday, June 16th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 3.21%. The ex-dividend date of this dividend is Wednesday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 21.99%.
COPYRIGHT VIOLATION NOTICE: “WealthTrust Axiom LLC Acquires 3,303 Shares of Gilead Sciences, Inc. (GILD)” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2654231/wealthtrust-axiom-llc-acquires-3303-shares-of-gilead-sciences-inc-gild.html.
GILD has been the topic of several research analyst reports. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $79.10 target price on the stock. in a research report on Monday, March 6th. Mizuho decreased their target price on shares of Gilead Sciences from $88.00 to $77.00 and set a “buy” rating on the stock in a research report on Wednesday, March 1st. Credit Suisse Group restated a “buy” rating and set a $79.00 target price on shares of Gilead Sciences in a research report on Wednesday, March 1st. Jefferies Group LLC reiterated a “buy” rating on shares of Gilead Sciences in a research report on Wednesday, March 22nd. Finally, Barclays PLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Gilead Sciences in a research report on Wednesday, March 22nd. Twelve research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $80.61.
In other news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $67.18, for a total transaction of $4,926,510.94. Following the completion of the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $214,973,917.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John Francis Cogan sold 9,943 shares of the firm’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total value of $668,666.75. Following the sale, the director now directly owns 47,562 shares of the company’s stock, valued at $3,198,544.50. The disclosure for this sale can be found here. Insiders have sold a total of 88,276 shares of company stock valued at $5,932,578 over the last ninety days. Company insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.